Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 30 Mar 2026 | Koen Van Dyck Head of Unit | Discussion on implementation of Regulation (EU) n° 2025/179 | — |
| 30 Mar 2026 | Koen Van Dyck Head of Unit | Discussion on implementation of Regulation (EU) n° 2025/179 | SRC |
| 20 Nov 2025 | Michele Piergiovanni Cabinet member | To give an update of recent development in the company and sector | — |
| 20 Nov 2025 | Michele Piergiovanni Cabinet member | To give an update of recent development in the company and sector | SRC |
| 23 Jun 2025 | Andreas Schwarz Cabinet member | Exchange on Life Sciences Strategy and next Framework Programme | — |
| 23 Jun 2025 | Alexandra Hild Cabinet member | Exchange on Life Sciences Strategy and next Framework Programme | — |
| 23 Jun 2025 | Andreas Schwarz Cabinet member | Exchange on Life Sciences Strategy and next Framework Programme | SRC |
| 23 Jun 2025 | Alexandra Hild Cabinet member | Exchange on Life Sciences Strategy and next Framework Programme | SRC |
| 26 Feb 2025 | Vilija Sysaite Cabinet member | Genomic research in Europe | — |
| 26 Feb 2025 | Vilija Sysaite Cabinet member | Genomic research in Europe | SRC |
| 26 Feb 2025 | Carmen Laplaza Santos Head of Unit | Exchange of views on how to leverage of genomics data to accelerate breakthroughs in precision medicine and to support the implementation of Horizon Europe | SRC |
| 26 Feb 2025 | Carmen Laplaza Santos Head of Unit | Exchange of views on how to leverage of genomics data to accelerate breakthroughs in precision medicine and to support the implementation of Horizon Europe | — |
| 03 Dec 2021 | Chris Uregian Cabinet member | Healthcare benefits of Cancer test | — |
| 03 Dec 2021 | Carole Mancel-Blanchard Cabinet member | Presentation of the merger case Illumina and Grail | — |
| 03 Dec 2021 | Joanna Stawowy Cabinet member | The public health benefits and competition issues arising out of the merger between Illumina and GRAIL | — |
| 03 Dec 2021 | Carole Mancel-Blanchard Cabinet member | Presentation of the merger case Illumina and Grail | SRC |
| 03 Dec 2021 | Chris Uregian Cabinet member | Healthcare benefits of Cancer test | SRC |
| 03 Dec 2021 | Katherine Power Cabinet member | Cancer Screening tests, Illumina-GRAIL Merger | SRC |
| 03 Dec 2021 | Eva Gerhards Cabinet member | Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy | — |
| 03 Dec 2021 | Katherine Power Cabinet member | Cancer Screening tests, Illumina-GRAIL Merger | — |
| 03 Dec 2021 | Eva Gerhards Cabinet member | Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy | SRC |
| 03 Dec 2021 | Joanna Stawowy Cabinet member | The public health benefits and competition issues arising out of the merger between Illumina and GRAIL | SRC |
| 12 Nov 2021 | Maurits-Jan Prinz Cabinet member | Challenges of the health industrial ecosystem | SRC |
| 12 Nov 2021 | Maurits-Jan Prinz Cabinet member | Challenges of the health industrial ecosystem | — |
| 29 Sept 2021 | Anthony Whelan Cabinet member | Illumina/GRAIL transaction, which in addition to important competition policy questions | — |
Mission & Goals
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
EU Legislative Interests
Illumina follows policy and legislative developments related to genomics, agri-genomics, public health, animal health, agriculture, forensics, biotechnology, data protection, science, and research policies. In particular, Illumina follows the discussions on the proposal for a EU Health Data Space (EHDS) and developments relating to the Regulations on medical devices (MDR) and In-vitro diagnostics (IVDR). It also engages in policy and regulatory initiatives relating to research and innovation in the EU (Horizon Europe), including more generally developments relating to EU research programs, with a focus on genomics research. Additionally, Illumina focuses on policy developments related to the Beating Cancer Plan, the 1+Million Genomes Initiative, the EU Action on Antimicrobial Resistance (AMR), the EU Covid-19 policy response, the implementation of the NextGenerationEU Plan, and the EU orphan medicines legislation. Moreover, an emphasis is also given to monitoring the review in scope and responsibilities of key institutional stakeholders such as the European Medicine Agency (EMA), the European Center for Disease Control (ECDC) and the European Health Emergency preparedness and Response Authority (HERA).
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
MedTech Europe https://www.medtecheurope.org/ EUCOPE https://www.eucope.org/ All.Can https://www.all-can.org/ European Cancer Organisation https://www.europeancancer.org/ American Chamber of Commerce to the EU https://www.amchameu.eu/ American European Community Association (AECA) https://aeca.org/
Organisation Members
See above